Resolvin E3 (RvE3) is an E-series resolvin derived from eicosapentaenoic acid (EPA) through stereoselective lipoxygenase pathways, acting as a specialized pro-resolving mediator that actively terminates inflammation and promotes tissue repair. RvE3 completes the E-series resolvin family alongside RvE1 and RvE2, providing redundancy and functional overlap in the resolution response. Its biosynthesis requires adequate EPA substrate, functional 15-LOX and 5-LOX enzymes, and occurs during Lipid mediator class switching as inflammation transitions from initiation to resolution.
Think of a fire brigade with three independent alarm systems. If your building catches fire, you want all three alarms to go off—not because one isn't enough, but because redundancy ensures the fire trucks arrive even if one system fails. RvE3 is the third alarm in the E-series resolvin fire brigade. RvE1 might be the smoke detector, RvE2 the heat sensor, and RvE3 the manual pull station. All three detect the same fire (inflammation), but through different sensors, and all three send fire trucks (anti-inflammatory signals) racing to the scene.
Now imagine one alarm system breaks—maybe the batteries die in the smoke detector (low EPA), or the wiring fails in the heat sensor (Oxidative Stress damages 15-LOX). If you only had one alarm, the building burns. But with three independent systems, the fire still gets reported and resolved. This is why RvE3 matters: it's not redundant in the wasteful sense—it's redundant in the life-saving sense. Evolution built backup systems for inflammation resolution because failed resolution means chronic inflammation, and chronic inflammation means death. RvE3 ensures that even when other E-series resolvins are impaired, the resolution machinery keeps running.
RvE3 biosynthesis begins with EPA (20:5n-3) and proceeds through coordinated lipoxygenase-mediated oxygenation:
Biosynthetic pathway:
- EPA → (via 15-LOX) → 15-hydroperoxy-EPA intermediate
- 15-hydroperoxy-EPA → (via 5-LOX) → 5,15-dihydroxy-EPA intermediate
- Stereoselective reduction and isomerization → RvE3 (5S,12R,18R-trihydroxy-EPA)
This pathway is activated during Lipid mediator class switching, the temporal transition from pro-inflammatory eicosanoid production (COX-2, early 5-LOX) to pro-resolving Specialized pro-resolving mediators (SPMs) biosynthesis. Key regulatory nodes include:
- COX-2 acetylation by aspirin → blocks prostaglandin synthesis, redirects substrate to 15-LOX
- Cellular redox state → Oxidative Stress impairs lipoxygenase function through direct enzyme oxidation
- EPA availability → substrate limitation is rate-limiting; plasma EPA <2% of total fatty acids correlates with SPM deficiency
- Enzyme expression → 15-LOX and 5-LOX transcription regulated by NF-κB, PPAR signaling, and HIF pathways
Receptor signaling cascade:
RvE3 binds G-protein coupled receptors (GPCRs), though specific receptor identity remains under investigation. Proposed mechanisms based on E-series resolvin family behavior:
graph TD
A[RvE3] -->|binds| B[GPCR candidate receptors]
B --> C["Gαi protein activation"]
C --> D["↓ cAMP via inhibited adenylyl cyclase"]
C --> E["βγ subunit release"]
D --> F["↓ PKA activity"]
F --> G["↓ NF-κB nuclear translocation"]
G --> H["↓ IL-1β, IL-6, TNF-α transcription"]
E --> I[PI3K/Akt pathway]
I --> J[Enhanced efferocytosis]
E --> K[ERK1/2 phosphorylation]
K --> L[Tissue regeneration signals]
Cellular effects:
- Neutrophil recruitment → RvE3 blocks CXCL1/IL-8-driven chemotaxis; IC₅₀ ~10-100 nM in vitro
- Efferocytosis → enhances macrophage clearance of apoptotic neutrophil via AKT pathway activation and CD86 downregulation
- Cytokine regulation → dose-dependent reduction in TNF-α, IL-1β, IL-6 secretion from activated macrophages
- Endothelial function → reduces VCAM-1 expression, limits leukocyte adhesion and transmigration
- Pain modulation → inhibits TRPV1 sensitization in dorsal root ganglia, reduces inflammatory pain thresholds
Metabolic inactivation:
RvE3 → (via Eicosanoid oxidoreductase (E)-type enzymes) → oxidized, inactive metabolites cleared renally. Half-life ~15-30 minutes in plasma, requiring continuous biosynthesis for sustained effect.
RvE3 represents the third pillar of E-series resolvin-mediated resolution, providing functional redundancy critical for robust inflammation termination. In cPNI practice, RvE3 deficiency rarely occurs in isolation—it manifests as part of global SPM insufficiency syndrome, characterized by:
Clinical presentation:
Diagnostic approach:
Connection to metamodels:
Metamodel 1 (Energy Distribution): Failed resolution is energetically catastrophic—unresolved inflammation diverts 30-50% of ATP production to immune cell activation, creating metabolic-exhaustion. RvE3 deficiency perpetuates this energy drain.
Metamodel 3 (Chronic Inflammation): RvE3 is a direct intervention target for breaking chronic inflammatory loops. Without adequate E-series resolvin signaling, acute inflammation never transitions to resolution phase, establishing chronic low-grade inflammation.
Intervention strategy:
-
Substrate optimization:
- EPA supplementation: 2-4g/day, preferably triglyceride or phospholipid form
- Target RBC EPA >4%, Omega-3 index >8%
- Co-administer with Vitamin E (400 IU mixed tocopherols) to protect EPA from oxidation
-
Enzyme pathway support:
-
Lipid mediator class switching triggers:
- Aspirin (low-dose): 75-100mg/day acetylates COX-2, promotes aspirin-triggered resolvin biosynthesis
- Exercise: acute Exercise triggers SPM production via IL-6 and cortisol surges
- Cold exposure: activates 15-LOX pathways through Noradrenaline-mediated signaling
-
Resolution monitoring:
Special populations:
- Post-COVID syndrome: profound SPM depletion, including RvE3; aggressive EPA/DHA repletion critical
- IBD patients: intestinal inflammation consumes SPMs locally; higher oral doses (4-6g EPA) required
- Elderly: age-related decline in 15-LOX expression; enzyme pathway support (antioxidants, Vitamin D) essential alongside EPA
- Biosynthetic origin: 5S,12R,18R-trihydroxy-EPA derived from EPA via 15-LOX and 5-LOX pathways
- Molecular weight: ~352 Da (C₂₀H₃₂O₅)
- Plasma half-life: 15-30 minutes; requires continuous biosynthesis for sustained activity
- Effective concentration: 10-100 nM range shows anti-inflammatory effects in vitro; plasma levels typically 1-10 ng/mL in healthy individuals
- EPA threshold: RBC EPA <2% of total fatty acids predicts RvE3 biosynthetic insufficiency
- Enzymatic redundancy: E-series resolvins (RvE1, RvE2, RvE3) provide functional overlap—deficiency typically multi-resolvin, not single-molecule
- Oxidative vulnerability: RvE3 biosynthesis impaired by Oxidative Stress through direct lipoxygenase enzyme oxidation; GSSG:GSH >1:10 correlates with reduced SPM production
- Resolution kinetics: RvE3 peaks 4-8 hours post-inflammatory stimulus during active resolution phase; premature decline or absence indicates failed Lipid mediator class switching
- Clinical target: Omega-3 index >8% (combined EPA+DHA as % of RBC fatty acids) supports optimal E-series resolvin biosynthesis
- Co-supplementation: Vitamin E (mixed tocopherols, 400 IU/day) protects EPA and RvE3 from lipid peroxidation; Aspirin (75-100mg/day) promotes aspirin-triggered E-series resolvin variants
- Specialized pro-resolving mediators (SPMs) — RvE3 is core member of SPM family mediating active inflammation resolution
- Resolvins — specifically E-series subfamily alongside RvE1 and RvE2
- RvE1 — synergistic functional partner; both target overlapping GPCRs and cellular pathways
- RvE2 — third member of E-series triad providing resolution redundancy
- EPA — direct omega-3 precursor; biosynthetic substrate availability is rate-limiting
- 15-LOX — primary oxygenase enzyme catalyzing first biosynthetic step from EPA
- 5-LOX — secondary oxygenase completing RvE3 stereoselective synthesis
- Lipid mediator class switching — temporal metabolic transition enabling RvE3 production during resolution phase
- Efferocytosis — RvE3 enhances macrophage clearance of apoptotic neutrophil via AKT pathway
- Eicosanoid oxidoreductase (E — metabolic inactivation pathway terminating RvE3 signaling
- COX-2 — competitive enzyme pathway; COX-2 acetylation by aspirin redirects substrate to resolvin biosynthesis
- NF-κB — transcription factor downregulated by RvE3 signaling, reducing pro-inflammatory cytokine signaling
- Oxidative Stress — primary mechanism impairing RvE3 biosynthesis through lipoxygenase enzyme damage
- Omega-3 — broader fatty acid family; EPA:arachidonic acid ratio determines pro-resolving vs pro-inflammatory balance
- Neutrophil — primary cellular target; RvE3 blocks chemotaxis and promotes apoptosis for clearance
- Chronic inflammation — clinical state resulting from failed resolution when RvE3 and other SPMs are deficient
- Resolution interval (R_i) — quantitative measure of resolution kinetics; RvE3 deficiency prolongs R_i beyond 6 hours
- IL-6 — pro-inflammatory cytokine suppressed by RvE3; also paradoxically triggers SPM biosynthesis in acute phase
- Aspirin — pharmaceutical trigger of aspirin-triggered resolvin biosynthesis including E-series variants
- Metabolic flexibility — systemic capacity impaired by unresolved inflammation consuming energy for chronic immune activation
- Exercise — physiological trigger of SPM production including RvE3 via acute stress response
- Cold exposure — activates sympathetic tone and 15-LOX pathways promoting E-series resolvin biosynthesis
- Inflammatory bowel disease — clinical condition with demonstrated RvE3 deficiency and therapeutic target for EPA supplementation
- Long COVID — post-viral syndrome characterized by global SPM depletion including E-series resolvins
- TRPV1 — pain receptor desensitized by RvE3, reducing inflammatory pain sensitization